Tang Qi, Zhao Xian-Sheng, Guo Ao, Cui Ruo-Tong, Song Huai-Le, Qi Zi-Yang, Pan Yi, Yang Yue, Zhang Fang-Fang, Jin Liang
School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China.
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
World J Stem Cells. 2022 Oct 26;14(10):744-755. doi: 10.4252/wjsc.v14.i10.744.
Osteoarthritis (OA) is considered to be a highly heterogeneous disease with progressive cartilage loss, subchondral bone remodeling, and low-grade inflammation. It is one of the world's leading causes of disability. Most conventional clinical treatments for OA are palliative drugs, which cannot fundamentally cure this disease. The stromal vascular fraction (SVF) from adipose tissues is a heterogeneous cell population. According to previous studies, it contains a large number of mesenchymal stem cells, which have been used to treat OA with good therapeutic results. This safe, simple, and effective therapy is expected to be applied and promoted in the future. In this paper, the detailed pathogenesis, diagnosis, and current clinical treatments for OA are introduced. Then, clinical studies and the therapeutic mechanism of SVF for the treatment of OA are summarized.
骨关节炎（OA）被认为是一种高度异质性疾病，伴有进行性软骨丢失、软骨下骨重塑和低度炎症。它是全球导致残疾的主要原因之一。大多数用于OA的传统临床治疗方法都是姑息性药物，无法从根本上治愈这种疾病。脂肪组织的基质血管成分（SVF）是一种异质性细胞群体。根据以往研究，它含有大量间充质干细胞，已被用于治疗OA，且治疗效果良好。这种安全、简单且有效的治疗方法有望在未来得到应用和推广。本文介绍了OA的详细发病机制、诊断方法及当前临床治疗方法。然后，总结了SVF治疗OA的临床研究及治疗机制。
